NCT04797247View on ClinicalTrials.gov

Study of Efficacy and Safety of LIB003 in Patient With CVD on Statins Requiring Additional LDL-C Reduction

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

900

Participants

Timeline

Start Date

April 22, 2021

Primary Completion Date

November 15, 2023

Study Completion Date

February 28, 2024

Conditions
Cardiovascular DiseasesHyper-LDL-cholesterolemia
Interventions
DRUG

lerodalcibep

PCSK9 inhibitor

Trial Locations (3)

45219

Sterling Research Group, Cincinnati

The Lindner Research Center, Cincinnati

45227

Metabolic & Atherosclerosis Research Center (MARC), Cincinnati

Sponsors

Collaborators (1)

Medpace, Inc.
All Listed Sponsors
collaborator

Medpace, Inc.

INDUSTRY

lead

LIB Therapeutics LLC

INDUSTRY